JRCT ID: jRCT2080223894
Registered date:07/05/2018
A MULTICENTER, DOUBLE-BLIND, RANDOMIZED, PLACEBO CONTROLLED STUDY OF VARLITINIB PLUS CAPECITABINE VERSUS PLACEBO PLUS CAPECITABINE IN PATIENTS WITH ADVANCED OR METASTATIC BILIARY TRACT CANCER AS SECOND-LINE SYSTEMIC THERAPY
Basic Information
| Recruitment status | completed |
|---|---|
| Health condition(s) or Problem(s) studied | |
| Date of first enrollment | 18/05/2018 |
| Target sample size | 30 |
| Countries of recruitment | Japan |
| Study type | Interventional |
| Intervention(s) | investigational material(s) Generic name etc : INN of investigational material : varlitinib Therapeutic category code : 429 Other antitumor agents Dosage and Administration for Investigational material : control material(s) Generic name etc : INN of investigational material : - Therapeutic category code : Dosage and Administration for Investigational material : |
Outcome(s)
| Primary Outcome | efficacy safety |
|---|---|
| Secondary Outcome | efficacy safety |
Key inclusion & exclusion criteria
| Age minimum | >= 20age old |
|---|---|
| Age maximum | Not applicable |
| Gender | Both |
| Include criteria | |
| Exclude criteria |
Related Information
| Primary Sponsor | |
|---|---|
| Secondary Sponsor | |
| Source(s) of Monetary Support | |
| Secondary ID(s) | NCT03093870,JapicCTI-183951 |
Contact
| Public contact | |
| Name | |
| Address | |
| Telephone | |
| ClinicalTrialInformation@cmic.co.jp | |
| Affiliation | |
| Scientific contact | |
| Name | |
| Address | |
| Telephone | |
| contact@aslanpharma.com | |
| Affiliation | |